BEYOND GENOME CONFERENCE, SAN FRANCISCO, June 21 /CNW/ - GenoLogics, a
leading developer of lab and data management software solutions for life
sciences research, today announced that it has penned an agreement with
Illumina, Inc. to become a technology partner and participant in
IlluminaConnect, a bioinformatics software program established by Illumina to
advance data integration and analysis among the life science community.
GenoLogics will build integrations into Geneus that support Illumina's
BeadArray technology platforms and software for both gene expression and
genotyping applications. Geneus includes science-specific modules that are
purposed for multiple genomics application areas, and is built on an
enterprise laboratory information management system (LIMS) platform designed
for scientific lab and data management.
Omoshile Clement, Ph.D., Senior Product Manager, Platforms at Illumina
commented, "We are very happy to welcome GenoLogics as a new IlluminaConnect
partner, and we look forward to working with them to develop integrations to
our technology platforms for genotyping and gene expression applications."
"I am very excited about our partnership with Illumina. We are looking
forward to offering Geneus with integrations to their BeadArray analysis
software, BeadStudio, which will enable our customers with gene expression and
genotyping applications to tie their data together using one integrating LIMS
system. We will work closely with Illumina to ensure we develop seamless
integrations that provide end-to-end solutions for researchers using Illumina
genomics software and technologies," said Jason Wilson, Product Manager at
The most significant benefit from this partnership for customers -this
integration to Illumina software will enable customers to interconnect the
Illumina technologies in their lab with a LIMS and data management system
developed specifically to address gene expression and genotyping workflows and
genomics applications. This will allow for smooth data flow from one system to
another with an integrating LIMS system that acts as the informatics backbone
in one or multiple labs.
GenoLogics CEO, Michael Ball adds, "Our partnership with Illumina extends
our network of strategic partners, building on one of our core
differentiators. Our strong ties with best-in-class vendors enable us to
provide end-to-end solutions for applications such as translational medicine
and systems biology."
GenoLogics' Geneus provides LIMS functionality specifically for gene
expression and genotyping applications and integrates to a wide variety of
genomics instruments and software from best-in-class vendors, such as
GenoLogics is the leading provider of bioinformatics software solutions
that help life science laboratories specializing in the field of proteomics,
genomics, and systems biology research to manage, integrate, and analyze
enormous volumes of scientific and lab data. The Company's mission is to
catalyze life sciences research with a collaborative data management software
platform, advancing the early detection, prevention, and treatment of disease.
For more information, please visit www.genologics.com.
Illumina, Inc. (NASDAQ: ILMN) is a leading developer, manufacturer, and
marketer of next-generation life science tools and integrated systems for the
large-scale analysis of genetic variation and biological function. Using our
proprietary technologies, we provide a comprehensive line of products and
services that currently serve the sequencing, genotyping, and gene expression
markets, and we expect to enter the market for molecular diagnostics. Our
customers include leading genomic research centers, pharmaceutical companies,
academic institutions, clinical research organizations, and biotechnology
companies. Our tools provide researchers around the world with the
performance, throughput, cost effectiveness, and flexibility necessary to
perform the billions of genetic tests needed to extract valuable medical
information from advances in genomics and proteomics. We believe this
information will enable researchers to correlate genetic variation and
biological function, which will enhance drug discovery and clinical research,
allow diseases to be detected earlier, and permit better choices of drugs for
individual patients. For more information, please visit www.Illumina.com.
For further information:
For further information: GenoLogics Life Sciences Software, Inc., Tanis
MacSween, Manager, Marketing Communications, (250) 483-7063,
email@example.com; Maurissa Bornstein, Public Relations Manager,
Illumina, Inc., Ph: (858) 332-5055, Email: firstname.lastname@example.org